Myxedema Coma or Crisis Follow-up

  • Author: Elena Citkowitz, MD, PhD, FACP; Chief Editor: George T Griffing, MD   more...
 
Updated: Nov 23, 2011
 

Further Inpatient Care

  • Closely monitor vital signs, electrolytes, and glucose until the levels are within reference ranges and the patient is alert.
  • Substitute oral medications for intravenous ones in patients who are extubated and eating.
  • Watch for signs of infection, myocardial ischemia, and congestive heart failure.
  • Patients who, before hospitalization, did not take their thyroid medication regularly must be evaluated to determine whether they require assistance in taking their thyroid hormone replacement every day.
  • Institute physical therapy to assist in strength training and reconditioning.
Next

Further Outpatient Care

  • Follow-up care is necessary to ensure compliance with thyroid hormone replacement.
  • If primary hypothyroidism was diagnosed, assess the TSH level every 6 weeks and adjust the T4 dose. Once a normal TSH level is obtained, it may be monitored yearly. If compliance is an issue, check the patient every 3-6 months.
  • In hypothyroidism secondary to pituitary dysfunction, monitor free T4 levels. The TSH level is not an accurate measure of thyroid function.
  • Obtain assurance that the precipitants of the initial presentation will not recur.
Previous
Next

Inpatient & Outpatient Medications

  • Oral levothyroxine is taken daily at least 1 hour before meals.
  • If adrenal insufficiency or pituitary dysfunction has been diagnosed, replacement hormones must be taken as appropriate.
Previous
Next

Transfer

  • Patients who are awake, no longer dependent on a ventilator, and medically stable may be transferred from the intensive care unit to a medical floor. Before the patient is discharged to return home, transfer to a skilled-care nursing facility for further care and rehabilitation may be necessary.
Previous
Next

Deterrence/Prevention

  • Patients with a history of thyroid resection or ablation for hyperthyroidism and persons with a history of Hashimoto thyroiditis are at risk for developing hypothyroidism, and the TSH level should be monitored yearly. Such patients should be informed that hypothyroidism could occur in the future. They should understand the symptoms that signal the condition and the need to seek medical attention for appropriate testing.
  • Patients who are likely to be noncompliant with medication regimens must have their thyroid function closely monitored.
  • In cold climates, inadequately heated residences are a significant cause of myxedema coma/crises in patients with undiagnosed or inadequately treated hypothyroidism.
Previous
Next

Complications

  • Adrenal crisis is a major complication if patients presenting with myxedema coma/crisis also have adrenal insufficiency and are not treated concomitantly with stress doses of intravenous corticosteroids.
  • Myocardial infarction can cause myxedema coma/crisis but may also be a complication of intravenous treatment with thyroid replacement hormones in patients whose myocardial function is already precarious.
Previous
Next

Prognosis

Observational studies have analyzed the predictors of survival for patients presenting with myxedema coma.

  • In a study of 11 patients with myxedema coma in which 7 survived, statistically significant factors correlated with survival included the following[7] :
    • Coma on entry
    • Lower Glasgow Coma Scale
    • High APACHE II score
  • The following factors were not significantly correlated with survival:
    • Age
    • Body temperature
    • Heart rate
    • Free T4, TSH
  • In a study of 23 consecutive patients presenting with myxedema coma, 11 of whom survived, statistically significant predictors of mortality included the following[14] :
    • Hypotension and bradycardia at presentation
    • Need for mechanical ventilation
    • Hypothermia that is not responsive to treatment
    • Sepsis
    • Intake of sedatives
    • Lower Glasgow Coma Scale
    • High APACHE II score
    • High Sequential Organ Failure Assessment (SOFA) score. The SOFA score at baseline was most predictive, and a day 3 score of more than 6 was highly predictive of a poor outcome.
Previous
Next

Patient Education

  • Patients must be counseled regarding the necessity of taking daily thyroid hormone replacement and of being monitored on a regular basis so that their TSH level remains within the normal range.
  • Patients with a history of Hashimoto thyroiditis or who have undergone thyroid irradiation or resection should be counseled that hypothyroidism might occur in the future. They should be familiarized with the symptoms that suggest the presence of hypothyroidism and should understand the necessity of seeking prompt medical attention for appropriate testing.
  • For excellent patient education resources, visit eMedicine's Endocrine System Center. Also, see eMedicine's patient education articles Thyroid Problems and Myxedema Coma.
Previous
 
Contributor Information and Disclosures
Author

Elena Citkowitz, MD, PhD, FACP  Clinical Professor of Medicine, Yale University School of Medicine; Director, Cholesterol Management Center, Director, Cardiac Rehabilitation, Department of Medicine, Hospital of St Raphael

Elena Citkowitz, MD, PhD, FACP is a member of the following medical societies: American College of Physicians, American Heart Association, National Lipid Association, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Stephanie L Lee, MD, PhD  Associate Professor, Department of Medicine, Boston University School of Medicine; Director of Thyroid Health Center, Associate Chief, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center; Fellow, Association of Clinical Endocrinology

Stephanie L Lee, MD, PhD is a member of the following medical societies: American College of Endocrinology, American Thyroid Association, and Endocrine Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Romesh Khardori, MD, PhD, FACP  Professor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, and Endocrine Society

Disclosure: Nothing to disclose.

Mark Cooper, MBBS, PhD, FRACP  Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

References
  1. Wall CR. Myxedema coma: diagnosis and treatment. Am Fam Physician. Dec 1 2000;62(11):2485-90. [Medline]. [Full Text].

  2. Fliers E, Wiersinga WM. Myxedema coma. Rev Endocr Metab Disord. May 2003;4(2):137-41. [Medline].

  3. Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. Jul-Aug 2007;22(4):224-31. [Medline].

  4. Nicoloff JT, LoPresti JS. Myxedema coma. A form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. Jun 1993;22(2):279-90. [Medline].

  5. Diekman MJ, Harms MP, Endert E, et al. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol. Apr 2001;144(4):339-46. [Medline]. [Full Text].

  6. Mathew V, Misgar RA, Ghosh S, Mukhopadhyay P, Roychowdhury P, Pandit K, et al. Myxedema coma: a new look into an old crisis. J Thyroid Res. 2011;2011:493462. [Medline]. [Full Text].

  7. Rodríguez I, Fluiters E, Pérez-Méndez LF, et al. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol. Feb 2004;180(2):347-50. [Medline]. [Full Text].

  8. Rehman SU, Cope DW, Senseney AD, et al. Thyroid disorders in elderly patients. South Med J. May 2005;98(5):543-9. [Medline].

  9. Sheu CC, Cheng MH, Tsai JR, et al. Myxedema coma: a well-known but unfamiliar medical emergency. Thyroid. Apr 2007;17(4):371-2. [Medline].

  10. Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid. Dec 1999;9(12):1167-74. [Medline].

  11. Hylander B, Rosenqvist U. Treatment of myxoedema coma--factors associated with fatal outcome. Acta Endocrinol (Copenh). Jan 1985;108(1):65-71. [Medline].

  12. Jordan RM. Myxedema coma. Pathophysiology, therapy, and factors affecting prognosis. Med Clin North Am. Jan 1995;79(1):185-94. [Medline].

  13. Taguchi T, Iwasaki Y, Asaba K, et al. Myxedema coma and cardiac ischemia in relation to thyroid hormone replacement therapy in a 38-year-old Japanese woman. Clin Ther. Dec 2007;29(12):2710-4. [Medline].

  14. Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008;12(1):R1. [Medline]. [Full Text].

  15. Rimar D, Kruzel-Davila E, Dori G, et al. Hyperammonemic coma--barking up the wrong tree. J Gen Intern Med. Apr 2007;22(4):549-52. [Medline]. [Full Text].

  16. Brent GA, Larsen PR, Davies TF. Hypothyroidism thyroiditis. In: Kronenberg HM, Melmed S, Polonsky KS, et al, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, Pa: Saunders/Elsevier; 2008.

  17. Wartofsky L. Myxedema coma. Endocrinol Metab Clin North Am. Dec 2006;35(4):687-98, vii-viii. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.